Related references
Note: Only part of the references are listed.Pathogenesis of Triple-Negative Breast Cancer
Fatemeh Derakhshan et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2022)
Multi-Targeting Approach in Glioblastoma Using Computer-Assisted Drug Discovery Tools to Overcome the Blood-Brain Barrier and Target EGFR/PI3Kp110β Signaling
Catarina Franco et al.
CANCERS (2022)
A Drug Screening Reveals Minocycline Hydrochloride as a Therapeutic Option to Prevent Breast Cancer Cells Extravasation across the Blood-Brain Barrier
Joana Godinho-Pereira et al.
BIOMEDICINES (2022)
Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy
Yingnan Si et al.
ENGINEERING IN LIFE SCIENCES (2021)
Understanding Patterns of Brain Metastasis in Triple-Negative Breast Cancer and Exploring Potential Therapeutic Targets
Yan Lv et al.
ONCOTARGETS AND THERAPY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Myocyte Enhancer Factor 2C as a New Player in Human Breast Cancer Brain Metastases
Sofia Galego et al.
CELLS (2021)
Impact of the Nuclear Envelope on Malignant Transformation, Motility, and Survival of Lung Cancer Cells
Silvio Terra Stefanello et al.
ADVANCED SCIENCE (2021)
Nuclear Lamin A/C Expression Is a Key Determinant of Paclitaxel Sensitivity
Elizabeth R. Smith et al.
MOLECULAR AND CELLULAR BIOLOGY (2021)
Behind Brain Metastases Formation: Cellular and Molecular Alterations and Blood-Brain Barrier Disruption
Joana Godinho-Pereira et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Therapy Based on the Regulation of Thiol-dependent Redox Systems
Vasco Branco et al.
CURRENT MEDICINAL CHEMISTRY (2020)
EGFR signaling pathway occupies an important position in cancer-related downstream signaling pathways of Pyk2
Ting Shen et al.
CELL BIOLOGY INTERNATIONAL (2020)
The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer
Lei Zhang et al.
MOLECULAR CANCER (2020)
Downregulation of circulating miR 802-5p and miR 194-5p and upregulation of brain MEF2C along breast cancer brain metastasization
Marta Sereno et al.
MOLECULAR ONCOLOGY (2020)
Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis
Sima Lev
BIOCHEMICAL SOCIETY TRANSACTIONS (2020)
EGFR Promotes the Development of Triple Negative Breast Cancer Through JAK/STAT3 Signaling
Xiang Song et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR
Miguel A. Ortega et al.
JOURNAL OF ONCOLOGY (2020)
Unique cellular protrusions mediate breast cancer cell migration by tethering to osteogenic cells
Aaron M. Muscarella et al.
NPJ BREAST CANCER (2020)
KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene
Melyssa S. Roberts et al.
BREAST CANCER RESEARCH (2020)
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Jing Yang et al.
MOLECULAR CANCER (2019)
Targeting the PI3-kinase pathway in triple-negative breast cancer
J. Pascual et al.
ANNALS OF ONCOLOGY (2019)
Cancer treatment and survivorship statistics, 2019
Kimberly D. Miller et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
Ali S. Alzahrani
SEMINARS IN CANCER BIOLOGY (2019)
Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials
Amaia Eleonora Maennling et al.
CANCERS (2019)
FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer
Pushpamali De Silva et al.
EBIOMEDICINE (2019)
MEF2 and the tumorigenic process, hic sunt leones
Eros Di Giorgio et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2018)
Targeting the PI3K pathway in cancer: are we making headway?
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Tumour cell invasiveness and response to chemotherapeutics in adipocyte invested 3D engineered anisotropic collagen scaffolds
Robert D. Hume et al.
SCIENTIFIC REPORTS (2018)
Hypermethylation of CCND2 in Lung and Breast Cancer Is a Potential Biomarker and Drug Target
Chin-Sheng Hung et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
FOXP1 enhances tumor cell migration by repression of NFAT1 transcriptional activity in MDA-MB-231 cells
Sevil Oskay Halacli
CELL BIOLOGY INTERNATIONAL (2017)
A Cyclin D2-derived peptide acts on specific cell cycle phases by activating ERK1/2 to cause the death of breast cancer cells
Lilian C. Russo et al.
JOURNAL OF PROTEOMICS (2017)
The Role of Class IA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunits in Glioblastoma
Kevin J. Pridham et al.
FRONTIERS IN ONCOLOGY (2017)
The role of the two splice variants and extranuclear pathway on Ki-67 regulation in non-cancer and cancer cells
Luca Chierico et al.
PLOS ONE (2017)
Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade
Janet L. Martin et al.
BREAST CANCER RESEARCH (2017)
The paradoxical functions of EGFR during breast cancer progression
Remah Ali et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2017)
Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3CβD1067V kinase domain mutation
E. Pazarentzos et al.
ONCOGENE (2016)
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
Patricia Mucci LoRusso
JOURNAL OF CLINICAL ONCOLOGY (2016)
Triple-negative breast cancer: treatment challenges and solutions
Joelle Collignon et al.
BREAST CANCER-TARGETS AND THERAPY (2016)
S6K is a morphogenic protein with a mechanism involving Filamin-A phosphorylation and phosphatidic acid binding
Karen M. Henkels et al.
FASEB JOURNAL (2015)
FOXP1 regulation via the PI3K/Akt/p70S6K signaling pathway in breast cancer cells
Sevil Oskay Halacli et al.
ONCOLOGY LETTERS (2015)
Breast Cancer: Epidemiology and Etiology
ZiQi Tao et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2015)
High EGFR gene copy number predicts poor outcome in triple-negative breast cancer
Heae Surng Park et al.
MODERN PATHOLOGY (2014)
被撤回的出版物: MMP9 activation triggered by epidermal growth factor induced FoxO1 nuclear exclusion in non-small cell lung cancer (Retracted article. See April, 2017)
Jun Pei et al.
TUMOR BIOLOGY (2014)
Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Ala and MAPK pathways
Jaemoo Chun et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2013)
microRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway
Wenjing Cui et al.
FEBS JOURNAL (2013)
MEF2 Is a Converging Hub for Histone Deacetylase 4 and Phosphatidylinositol 3-Kinase/Akt-Induced Transformation
Eros Di Giorgio et al.
MOLECULAR AND CELLULAR BIOLOGY (2013)
Jolkinolide B induces apoptosis in MCF-7 cells through inhibition of the PI3K/Akt/mTOR signaling pathway
Hui-Yu Xu et al.
ONCOLOGY REPORTS (2013)
Inhibition of EGF/EGFR activation with naphtho[1,2-b]furan-4,5-dione blocks migration and invasion of MDA-MB-231 cells
Chi-Ying Hsieh et al.
TOXICOLOGY IN VITRO (2013)
Anti-Cancer Effect of IN-2001 in MDA-MB-231 Human Breast Cancer
Kyung Nan Min et al.
BIOMOLECULES & THERAPEUTICS (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
FOXP1, an Estrogen-Inducible Transcription Factor, Modulates Cell Proliferation in Breast Cancer Cells and 5-Year Recurrence-Free Survival of Patients with Tamoxifen-Treated Breast Cancer
Takashi Shigekawa et al.
Hormones & Cancer (2011)
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis
Bhumsuk Keam et al.
BREAST CANCER RESEARCH (2011)
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality
Elena Lopez-Knowles et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer
Olivier Rixe et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL
Philip J. Brown et al.
BLOOD (2008)
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non-small-cell lung cancer
Pasi A. Jaenne et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
E. de Azambuja et al.
BRITISH JOURNAL OF CANCER (2007)
Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer
Ralph G. Zinner et al.
CLINICAL CANCER RESEARCH (2007)
Breast tumor kinase (Protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells
Julie Hanson Ostrander et al.
CANCER RESEARCH (2007)
Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line
S Skvortsov et al.
APOPTOSIS (2005)
A small molecule-kinase interaction map for clinical kinase inhibitors
MA Fabian et al.
NATURE BIOTECHNOLOGY (2005)
Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivoi
MK Nyati et al.
CLINICAL CANCER RESEARCH (2004)
Cl-1033, an irreversible pan-erbB receptor inhibitor and its potential atmlication for the treatment of breast cancer
LF Allen et al.
SEMINARS IN ONCOLOGY (2003)
Share Paper
